About


Medicines affect everyone’s lives. But the development of new medicines has stagnated.
Verseon’s mission is to address this problem.

Founders

Adityo Prakash

Adityo Prakash

Adityo has guided the development of Verseon’s technology and business direction. Previously, he was co-founder and CEO of Pulsent Corp. As the principal inventor of Pulsent’s technology that forms a key part of today’s video streaming solutions, he was instrumental in guiding technology development, marketing and business strategy. He is an inventor on 40 patents and received his BS in physics and mathematics from Caltech.

Eniko Fodor

Eniko Fodor

Eniko has guided Verseon’s technology and drug pipeline development and operational growth and has also overseen its finance and accounting functions through various stages. Previously, she was co-founder and COO of Pulsent Corp. An inventor of that company’s original technology, she was instrumental in growing the company and developing its products and technology. Eniko is an inventor on 25 patents and received her BS in physics from Universitatea Babes-Bolyai, Kolozsvár, Romania.

David Kita

David Kita, PhD

David has led the development of Verseon’s computational design platform and growing drug pipeline. Previously, as Director of R&D at Pulsent Corp, he helped build the company’s novel video-compression and signal processing technology. Before Pulsent, as Director of Bioinformatics at Hyseq Inc., he built one of the industry's first bioinformatics platforms. David is an inventor on 38 patents and received his BS, MS & PhD in astrophysics from the University of Wisconsin, Madison.

Team Member Highlights

Adityo Prakash

David Williams, PhD

David oversees the development and maintenance of Verseon's platform technology He is experienced in running successful computational physics and chemistry programs. During his tenure at Stanford Linear Accelerator, he led large research teams in high-energy physics simulations. David is an inventor on 7 patents and received his BS in physics from Boston University and his PhD in high-energy physics from MIT.

Eniko Fodor

Anirban Datta, PhD

Anirban oversees all discovery biology and characterization of Verseon's drugs from in vitro through in vivo validation and into the clinic. Before joining Verseon, he developed considerable experienced in cancer cell biology, biochemistry, and novel bioassay development. At UCSF, he elucidated molecular signaling pathways in cancer metastasis. He also led the development of 3D cell-culture assays at Pharmacomatrix. Anirban is author of 22 peer-reviewed papers. He received his BS in physics and biology from the University of Chicago and his PhD in cellular and molecular biology from the University of Pennsylvania.

David Kita

Kevin Short, PhD

Kevin heads Verseon's medicinal chemistry campaigns. His extensive experience in drug discovery includes planning, program evaluation, and business development. Prior to joining Verseon, he led programs from inception to clinic at Johnson & Johnson and Ontogen. He is an inventor on 8 patents. Kevin received his BS in chemistry from Imperial College and his PhD in chemistry from the University of Exeter.

David Kita

Ki C. Wong

Ki C. oversees Verseon's software infrastructure. He has an extensive background in software engineering and system architecture. Prior to joining Verseon, he executed critical database infrastructure and database infrastructure projects for PayPal. He also spearheaded PayPal's early adoption of container technologies. Ki C. is an inventor on 2 patents. He received his BS in physics from Caltech and his MA in physics from UCSB.

David Kita

Carver C. Farrow, II

Carver oversees Verseon's legal affairs. He brings expertise in contract law, debt and equity financing, IP prosecution, and operational management to the company. As General Counsel for Speech Morphing he managed the company's legal and operational matters. In addition to running his own law practice, Carver also served as Technology Counsel for Pulsent Corporation. Carver received his BS in applied physics from Caltech and his JD from UCLA.

Clinical and Scientific Advisors

Steven Chu PhD
Professor, Stanford
Fmr. US Energy Secretary

Steven Chu is currently Professor of Physics and Molecular and Cellular Physiology at Stanford University. Previously, he was the U.S. Secretary of Energy from 2009 to 2013. He has also served on the faculty of University of California, Berkeley and as director of the Lawrence Berkeley National Laboratory from 2004 to 2009. He was awarded the Nobel Prize in Physics in 1997 for his work on laser cooling of atoms at Bell Labs.

Francis J. Doyle, III, PhD
Dean, Harvard Paulson School of Engineering

Frank Doyle is dean of the Harvard John A. Paulson School of Engineering and Applied Sciences and a member of the National Academy of Medicine. In early 2021, he became a member of the National Academy of Engineering for his insights into natural biological control systems and for engineering innovative diabetes control devices. Professor Doyle is co-principal investigator of the artificial pancreas project. His research group also studies circadian rhythms from a control-systems standpoint and is investigating the mechanisms and biomarkers for Post Traumatic Stress Disorder (PTSD).

Robert Karr, MD
CSO, Tioma
Fmr. VP R&D, Pfizer

Robert Karr is Chief Scientific Officer at Tioma, an immuno-oncology company developing antibody treatments for solid and hematologic cancers. Previously, he was the Senior Vice President of R&D Strategy at Pfizer. During his extensive career in the pharmaceutical industry, Dr. Karr has held various senior executive positions at Idera Pharmaceuticals, Pfizer, and Warner-Lambert. Prior to his career in industry, Dr. Karr completed his internship, residency, and fellowship at Washington University School of Medicine and held a faculty position at University Iowa College of Medicine.

Trevor M. Jones, PhD
Professor, UCL,
Fmr. Head of R&D, Wellcome

Trevor Jones is the joint UK-US Covid Strategy Coordinator and a visiting professor at King's College London. He also advises the Wales Government on the future of the NHS as a member of The Bevan Commission. Professor Jones is a non-executive director of the new life science investment fund, Arix Bioscience Plc and the Oxford-based Drug Discovery company, e-Therapeutics plc. He was formerly Head of R&D at the Wellcome Foundation, where he was main board director for Research & Development and was involved in the introduction of the HIV/AIDS drug AZT.

Rt Hon. Lord Ajay Kakkar, MB PhD
Professor, UCL

Ajay Kakkar is Professor of Surgery at University College Hospital London and a life peer in the House of Lords. Author of over 200 scientific papers, Lord Kakkar is a renowned expert in the prevention and treatment of venous and arterial thromboembolic disease. He is Chairman of University College London Partners and Director of the Thrombosis Research Institute. Lord Kakkar completed his medical degree at King’s College London and received a PhD from Imperial College London.

C. Michael Gibson, MD
Professor, Harvard Medical School

Michael Gibson is a distinguished clinical researcher and interventional cardiologist. He is Professor of Medicine at Harvard Medical School and a practicing interventional cardiologist and cardiovascular researcher at Beth Israel Deaconess Medical Center. Dr. Gibson has pioneered novel measures of coronary blood flow that are widely used today and has been the lead investigator on several large antiplatelet and anticoagulant trials.

John Deanfield, MB FRCP
Professor, UCL

John Deanfield is the British Heart Foundation Vandervell Professor of Cardiology and Director of the National Centre for Cardiovascular Disease Prevention and Outcomes at University College Hospital, London. Professor Deanfield is a pioneer in cardiology and one of the leading investigators in cardiovascular disease. He is an author on over 500 papers and serves on numerous advisory and journal editorial boards.

Keith Fox, MB ChB
Professor, University of Edinburgh

Keith Fox is British Heart Foundation and Duke of Edinburgh Professor of Cardiology at University of Edinburgh. Professor Fox is an award-winning cardiologist and founding fellow of the European Society of Cardiology. He is an expert in acute coronary artery disease and has been the lead investigator on multiple novel anticoagulant trials. In 2015 Professor Fox was honored as one of four "Legends in Cardiology" by the American College of Cardiology and the European Society of Cardiology.

Gregory Lip, MD
Professor, University of Liverpool

Gregory Lip is Price-Evans Chair of Cardiovascular Medicine at the University of Liverpool. Professor Lip is one of the leading experts in the understanding and treatment of atrial fibrillation and was elected to the Thomson Reuters Science Watch list of "World’s Most Influential Scientific Minds 2014." He spearheaded research leading to the introduction of two widely used scores for assessing stroke and bleeding risk.

Renato Lopes, MD PhD
Professor, Duke University & Federal University of Sao Paulo

Renato Lopes is a Professor of Medicine at Duke University Medical Center and the Federal University of Sao Paulo. Professor Lopes’ research interests include the epidemiology and treatment of patients with combined atrial fibrillation and acute coronary syndromes, as well as new cardiology biomarkers. He helped establish the Brazilian Clinical Research Institute and currently serves as its Executive Director.